LISSONI ANDREA ALBERTO

Colombo, N., Biagioli, E., Harano, K., Galli, F., Hudson, E., Antill, Y., et al. (2024). Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial. THE LANCET ONCOLOGY, 25(9), 1135-1146 [10.1016/S1470-2045(24)00334-6]. Detail

Bianchi, T., Grassi, T., Bazzurini, L., Testa, F., Corti, J., Pecis Cavagna, G., et al. (2024). The paradigm shift in advanced ovarian cancer: Outcomes of extensive primary cytoreductive surgery. A single-center retrospective analysis. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 50(9 (September 2024)) [10.1016/j.ejso.2024.108523]. Detail

Marino, G., Grassi, T., De Ponti, E., Negri, S., Testa, F., Giuliani, D., et al. (2024). Outcome of patients with stage I immature teratoma after surveillance or adjuvant chemotherapy. FRONTIERS IN ONCOLOGY, 14 [10.3389/fonc.2024.1330481]. Detail

Marino, G., Grassi, T., De Ponti, E., Testa, F., Negri, S., Giuliani, D., et al. (2024). Fertility outcomes in stage I ovarian immature teratomas. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 34(9), 1416-1422 [10.1136/ijgc-2024-005534]. Detail

Colombo, N., Gadducci, A., Landoni, F., Lorusso, D., Sabbatini, R., Artioli, G., et al. (2023). Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study. GYNECOLOGIC ONCOLOGY, 175(August 2023), 182-189 [10.1016/j.ygyno.2023.05.065]. Detail